AI Maverick Intel Issues Shares for HEAL Access Canada Acquisition

AI Maverick Intel (OTC: AIMV) has taken a significant step forward in its acquisition of HEAL Access Canada Inc. by issuing 76.5 million common shares to HEAL Group Holdings as the initial tranche of consideration under their Right of First Refusal Agreement. The total consideration has been adjusted from 120 million to 100 million AIMV common shares, with the companies continuing toward a definitive agreement. This move signals AIMV's commitment to expanding its footprint in the healthcare AI space, leveraging HEAL Access Canada's expertise. Additionally, AIMV plans to pursue an uplisting to the OTCQB Venture Market as part of its broader capital markets strategy, aiming to enhance liquidity and visibility among institutional investors.

AI Maverick Intel, Inc. is a company focused on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. By evaluating strategic acquisitions, partnerships, and scalable platforms, the company aims to drive long-term shareholder value. The acquisition of HEAL Access Canada is expected to bolster AIMV's capabilities in AI-driven healthcare solutions, a rapidly growing sector with immense potential. The issuance of shares to HEAL Group Holdings demonstrates the collaborative nature of this deal, aligning interests between the two entities.

InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, is facilitating the dissemination of this news to a wide audience. InvestorWire offers advanced wire-grade press release syndication, reaching millions of social media followers and 5,000+ outlets. For investors seeking the latest updates on AIMV, the company’s newsroom is available at http://ibn.fm/AIMV. This announcement underscores the growing trend of AI companies consolidating to gain competitive advantages in healthcare, data analytics, and beyond.